These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17822802)

  • 1. Formulation of Neulasta (pegfilgrastim).
    Piedmonte DM; Treuheit MJ
    Adv Drug Deliv Rev; 2008 Jan; 60(1):50-8. PubMed ID: 17822802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability studies of anticancer agent bis(4-fluorobenzyl)trisulfide and synthesis of related substances.
    Bao Y; Mo X; Xu X; He Y; Xu X; An H
    J Pharm Biomed Anal; 2008 Nov; 48(3):664-71. PubMed ID: 18678459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
    Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA
    Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation development and stability testing of oral morphine solution utilizing preformulation approach.
    Preechagoon D; Sumyai V; Tontisirin K; Aumpon S; Pongjanyakul T
    J Pharm Pharm Sci; 2005 Aug; 8(2):362-9. PubMed ID: 16124948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegfilgrastim (Neulasta) for prevention of febrile neutropenia.
    Med Lett Drugs Ther; 2002 May; 44(1130):44-5. PubMed ID: 12011756
    [No Abstract]   [Full Text] [Related]  

  • 6. Self-buffering antibody formulations.
    Gokarn YR; Kras E; Nodgaard C; Dharmavaram V; Fesinmeyer RM; Hultgen H; Brych S; Remmele RL; Brems DN; Hershenson S
    J Pharm Sci; 2008 Aug; 97(8):3051-66. PubMed ID: 18023013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid formulation assessment of filgrastim therapeutics by a thermal stress test.
    Alebouyeh M; Tahzibi A; Yaghoobzadeh S; Zahedy ET; Kiumarsi S; Soltanabad MH; Shahbazi S; Amini H
    Biologicals; 2016 May; 44(3):150-6. PubMed ID: 27017583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and in vitro evaluation of a cosmetic emulsion from almond oil.
    Akhtar N; Ahmad M; - G; Masood MI; Aleem M
    Pak J Pharm Sci; 2008 Oct; 21(4):430-7. PubMed ID: 18930867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation development of frozen parenteral dosage forms.
    Chilamkurti RN
    J Parenter Sci Technol; 1992; 46(4):124-9. PubMed ID: 1453281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
    Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
    Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of formulation properties on chemical stability of captopril in aqueous preparations.
    Kristensen S; Lao YE; Brustugun J; Braenden JU
    Pharmazie; 2008 Dec; 63(12):872-7. PubMed ID: 19177902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human granulocyte colony stimulating factor pre-screening and screening of stabilizing carbohydrates and polyols.
    Pavisić R; Hock K; Mijić I; Horvatić A; Gecan M; Sedić M; Krajacić MB; Cindrić M
    Int J Pharm; 2010 Mar; 387(1-2):110-9. PubMed ID: 20005931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability study of ambroxol hydrochloride sustained release pellets coated with acrylic polymer.
    Kibria G; Islam KM; Jalil RU
    Pak J Pharm Sci; 2009 Jan; 22(1):36-43. PubMed ID: 19168418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring Effects of Excipients, Formulation Parameters and Mutations on the High Order Structure of Filgrastim by NMR.
    Aubin Y; Hodgson DJ; Thach WB; Gingras G; Sauvé S
    Pharm Res; 2015 Oct; 32(10):3365-75. PubMed ID: 26043856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of a freeze-dried recombinant streptokinase formulation without serum albumin.
    López M; González LR; Reyes N; Sotolongo J; Pujol V
    J Clin Pharm Ther; 2004 Aug; 29(4):367-73. PubMed ID: 15271104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta
    Wynne C; Schwabe C; Vincent E; Schueler A; Ryding J; Ullmann M; Ghori V; Kanceva R; Stahl M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00578. PubMed ID: 32333641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on preparation technology of aconitine liposomes].
    Dong WW; Zhang YF; Liu XP; Geng DQ
    Zhong Yao Cai; 2008 Sep; 31(9):1413-5. PubMed ID: 19180972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.
    Anhorn MG; Mahler HC; Langer K
    Int J Pharm; 2008 Nov; 363(1-2):162-9. PubMed ID: 18672043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of freeze-thawing on the long-term stability of calcium levofolinate in 5% dextrose stored on polyolefin infusion bags.
    Lebitasy M; Hecq JD; Athanassopoulos A; Vanbeckbergen D; Jamart J; Galanti L
    J Clin Pharm Ther; 2009 Aug; 34(4):423-8. PubMed ID: 19583675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and biopharmaceutical evaluation of extended release formulation of tramadol hydrochloride based on osmotic technology.
    Kumar P; Singh S; Mishra B
    Acta Pharm; 2009 Mar; 59(1):15-30. PubMed ID: 19304555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.